Jennison Associates (PVLA) reports 960,619-share, 6.7% position in Palvella Therapeutics

Rhea-AI Filing Summary

Jennison Associates LLC reports a significant ownership stake in Palvella Therapeutics Inc. common stock. As of June 30, 2026, Jennison beneficially owned 960,619 shares, representing 6.7% of the class.

Jennison has sole power to vote these 960,619 shares and shared power to dispose of 960,619 shares, with no shared voting power and no sole dispositive power reported.

Key Figures

Beneficially owned shares: 960,619 shares Percent of class: 6.7% Sole Voting Power: 960,619 shares +3 more

6 metrics

Beneficially owned shares 960,619 shares Beneficial ownership of Palvella Therapeutics common stock as of June 30, 2026

Percent of class 6.7% Portion of Palvella Therapeutics common stock class beneficially owned

Sole Voting Power 960,619 shares Shares over which Jennison Associates LLC has sole power to vote

Shared Voting Power 0 shares Shares over which Jennison Associates LLC has shared power to vote

Sole Dispositive Power 0 shares Shares over which Jennison Associates LLC has sole power to dispose

Shared Dispositive Power 960,619 shares Shares over which Jennison Associates LLC has shared power to dispose

Key Terms

beneficially owned, Sole Voting Power, Shared Dispositive Power, Percent of class, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 960619"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"5 | Sole Voting Power 960,619.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Shared Dispositive Power financial

"8 | Shared Dispositive Power 960,619.00"

Percent of class financial

"Item 4. | Ownership (b) | Percent of class: 6.7 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

CUSIP Number financial

"(e) | CUSIP Number(s): 697947109"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 10:48 AM Accepted by SEC EDGAR 08/03/2026 - 10:48 AM Learn about SEC filing dates

FAQ

What percentage of Palvella Therapeutics (PVLA) does Jennison Associates LLC own?

Jennison Associates LLC reports beneficial ownership of 6.7% of Palvella Therapeutics Inc. common stock, based on 960,619 shares held as of June 30, 2026.

How many Palvella Therapeutics (PVLA) shares does Jennison Associates LLC hold?

Jennison Associates LLC reports holding 960,619 shares of Palvella Therapeutics Inc. common stock, representing 6.7% of the class as of June 30, 2026.

What voting power does Jennison Associates LLC have in Palvella Therapeutics (PVLA)?

Jennison Associates LLC reports sole voting power over 960,619 shares of Palvella Therapeutics Inc. and no shared voting power over any shares.

What dispositive power does Jennison Associates LLC report over its PVLA shares?

Jennison Associates LLC reports shared dispositive power over 960,619 shares of Palvella Therapeutics Inc. and no sole dispositive power over any shares.

Who signed the Schedule 13G for Jennison Associates LLC regarding Palvella Therapeutics (PVLA)?

The Schedule 13G was signed by Beata Markowicz, Senior Vice President, Compliance, on August 3, 2026, on behalf of Jennison Associates LLC.

What security class of Palvella Therapeutics (PVLA) is covered by Jennison’s Schedule 13G?

The filing covers Common Stock of Palvella Therapeutics Inc., identified by CUSIP 697947109, with Jennison Associates LLC as a beneficial owner.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

PALVELLA THERAPEUTICS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

697947109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 697947109

1

Names of Reporting Persons

Jennison Associates LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 960,619.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 960,619.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

960,619.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PALVELLA THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 353 W. Lancaster Avenue, Suite 200, Wayne, PA 19087
Item 2.
(a)	Name of person filing: Jennison Associates LLC
(b)	Address or principal business office or, if none, residence: 55 East 52nd Street, New York, NY 10055
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 697947109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 960619
(b)	Percent of class: 6.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 960619
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 960619
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Jennison Associates LLC

Signature:	Beata Markowicz
Name/Title:	Senior Vice President, Compliance
Date:	08/03/2026